Announcement • 18h
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation Committee Eikon Therapeutics, Inc. appointed Ma. Fatima D. Francisco as an independent director to its Board of Directors, where Ms. Francisco will also serve on the Board’s Compensation Committee. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations, and general management. She also serves on the Board of Directors of HP Inc. and Nestlé S.A., and previously served on the Board of Directors of Organon & Co. Announcement • Aug 13
Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced Melanoma Eikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data. The DMC recommended that the TeLuRide-006 study continue as planned in all other respects. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses to malignancy. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced solid tumors. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. TeLuRide-006 (NCT06697301) is a global, multicenter, randomized, double-blind, adaptive Phase 2/3 registrational trial of EIK1001 or placebo, in combination with pembrolizumab, as first-line therapy for participants with advanced cutaneous melanoma. Announcement • Aug 11
Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory Board Eikon Therapeutics, Inc. had announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently served as Vice President and Head of Discovery Chemistry at Merck Research Laboratories. A native of Scotland, Dr. Johnny Bennett earned his undergraduate and Ph.D. degrees from Heriot-Watt University in Edinburgh before beginning his career with N.V. Organon in the Netherlands in 1997. There, he worked across neuroscience and cardiovascular disease, with his neuroscience research culminating in the discovery of sugammadex (Bridion), the first medicine developed to rapidly reverse neuromuscular blockade following surgery. In recognition of this achievement, he was a co-recipient of both the American Chemical Society Heroes of Chemistry Award and the Royal Society of Chemistry Malcolm Campbell Memorial Award for outstanding contributions to the biological and medical sciences. After relocating to the United States in 2011, Dr. Bennett joined Merck as Senior Director of Discovery Chemistry in West Point before moving to lead the Discovery Chemistry organization at the company’s Boston site in 2012. He had since taken on a series of increasingly broad leadership roles within Merck’s Discovery Chemistry group, and was promoted to Vice President in 2022. Dr. Bennett also served as interim Head of Discovery Oncology in 2024. Earlier in 2026, Dr. Bennett was promoted to his current role of Vice President and Head of Discovery Chemistry. Dr. Bennett joined a distinguished group of scientists serving on the company’s Scientific Advisory Board, including: Eric Betzig, Ph.D., is a co-founder of Eikon, a professor at the University of California, Berkeley, and a 2014 Nobel laureate whose pioneering work in super-resolution microscopy helped provide the technological foundation for Eikon’s proprietary single molecule tracking (SMT) platform. Thomas Cech, Ph.D., is a Distinguished Professor of Biochemistry at the University of Colorado, Boulder and a 1989 Nobel laureate whose research established the ability of certain RNA molecules to behave as enzymes. Trey Ideker, Ph.D., is the Director of the Big Data Institute at the University of Oxford (UK), and a Professor of Medicine at the University of California, San Diego. He is a leader in computational approaches to understanding complex biological processes, including those associated with disease pathogenesis. Robert “Tij” Tjian, Ph.D., is a co-founder of Eikon, a professor of biochemistry, biophysics and structural biology and the Li Ka Shing Chancellor's Chair in Biology at the University of California, Berkeley, and former president of the Howard Hughes Medical Institute. Wendy B. Young, Ph.D., is an accomplished medicinal chemist and drug discovery executive who previously led small-molecule drug discovery research at Genentech and now advises biotechnology companies and serves as an advisor to GV (Google Ventures). 
